Abel Hall LLC
IKT icon

Abel Hall LLC’s Inhibikase Therapeutics IKT Stock Holding History

Abel Hall LLC’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$110K Buy
53,311
+6,959
+15% +$15.8K 0.02% 769
2026
Q2 		$94.1K Buy
46,352
+31,789
+218% +$56.9K 0.02% 843
2026
Q1 		$24.5K Buy
+14,563
New +$25.9K 0.01% 786

Other funds holding IKT

Pinnacle Wealth Planning Services
Pinnacle Wealth Planning Services Mansfield, Ohio $1.03B AUM 22.32% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
True Wealth Design
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
SJS Investment Consulting
SJS Investment Consulting Sylvania, Ohio $993M AUM 16.29% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Abel Hall LLC's IKT Position: Q3 2026 in Review

Abel Hall LLC increased its Inhibikase Therapeutics (IKT) stake by 15% in Q3 2026, buying an estimated $15.8K and bringing the position to 53,311 shares worth $110K. The position accounts for 0.02% of the portfolio, ranked #769.

Abel Hall LLC first reported a position in IKT in Q1 2026 and has held it in 3 quarters since. 10 funds tracked by Wall St. Rank hold IKT as of Q3 2026.

  • Abel Hall LLC held 53,311 shares of Inhibikase Therapeutics worth $110K as of Q3 2026.
  • Abel Hall LLC bought 6,959 Inhibikase Therapeutics shares in Q3 2026, an estimated $15.8K.
  • Inhibikase Therapeutics made up 0.02% of Abel Hall LLC's portfolio in Q3 2026, its #769 holding.
  • Abel Hall LLC first reported a position in Inhibikase Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 10 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.